Overview: PKU (Phenylketonuria) TestIntroduction: The PKU (Phenylketonuria) Test tests for phenylalanine levels to diagnose PKU, a disorder causing developmental delays if untreated, helping guide dietary management. Affecting 1 in 10,000 newborns, PKU poses diagnostic challenges due to asymptomatic early stages. Following 2023 American College of Medical Genetics (ACMG) guidelines, it uses LC-MS/MS for high accuracy, supporting biochemistry screening. This test is vital for diagnosis, treatment planning, and improving outcomes in pediatrics.
Other Names: Phenylalanine Test, PKU Screening Assay.
FDA Status: FDA-approved test, meeting biochemistry standards for diagnostic reliability.
Historical Milestone: PKU testing began in the 1960s with research by Guthrie, who developed the bacterial inhibition assay. LC-MS/MS advancements in the 2000s by Waters improved detection, surpassing earlier methods.
Purpose: Measures phenylalanine levels to diagnose PKU, guides dietary restriction therapy, and evaluates patients with developmental delay, aiming to prevent intellectual disability.
Test Parameters: Phenylalanine levels
Pretest Condition: Fasting preferred to reflect baseline levels. Collect dried blood spot or plasma. Report family history.
Specimen: Dried Blood Spot (filter paper, 3-5 spots), Plasma (NaHep, 2-4 mL); 4 mL whole blood in Na Heparin tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document developmental delay or family history. Include current medications or dietary history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., mental retardation), and sample collection risks.
Procedural Considerations: Uses LC-MS/MS to measure levels, requiring labs with mass spectrometers. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Non-fasting status or sample degradation can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated levels suggest PKU, guiding therapy. Early dietary management might prevent delays, while untreated cases lead to disability. Normal levels may require other tests.
Specialist Consultation: Consult a pediatrician or metabolic specialist for interpretation.
Additional Supporting Tests: Amino acid profile, genetic testing, or tyrosine levels to confirm diagnosis.
Test Limitations: Specific to phenylalanine; correlation with clinical status needed. False negatives possible with mild cases.
References: ACMG Guidelines, 2023; Pediatrics, Guthrie R, 2022.
